Herbal Tea for Blood Sugar: What RCTs Actually Show

Non-green herbal teas may improve fasting glucose and HbA1c in people with type 2 diabetes, but the evidence cannot yet tell you which tea belongs at the top of the cabinet. A 2025 systematic review and meta-analysis pooled 14 randomized controlled trials involving 551 people with type 2 diabetes and found statistically significant improvements in both measures. That is a real signal. It is not a species-by-species ranking, a dose prescription, or permission to treat a tea bag as diabetes medication.

The review excluded Camellia sinensis, the plant behind green and black tea. That matters because green tea already gets most of the metabolic-health attention. The available randomized evidence instead concerns herbal infusions made from other plants, using 2 to 20 grams of plant material per day.

The verdict: a category-level signal, not an evidence-ranked tea chart

The 2025 review found lower fasting blood glucose across the pooled trials (P=0.0034) and lower HbA1c (P=0.045). HbA1c reflects average blood glucose over roughly the preceding two to three months, so it is the more clinically familiar of the two markers. Still, the published abstract does not provide the absolute mean changes or 95% confidence intervals needed to judge whether the HbA1c difference reached a clinically meaningful range, often considered roughly 0.3 to 0.5 percentage points.

That missing precision changes how the result should be used. Statistical significance tells us the pooled result was unlikely to arise from random variation under the analysis assumptions. It does not tell us whether the change was large enough to alter medication decisions, complication risk, or daily glucose management for an individual person.

The review also does not support a reliable species ranking. The trials were too few, the preparations too varied, and the daily plant-material doses too broad to separate hibiscus, cinnamon, chamomile, or other herbs with confidence. Hibiscus is a reasonable candidate for further study because it is rich in anthocyanins, but it has not earned a gold-medal ranking from this meta-analysis.

Herbal tea has randomized-trial support as a potentially useful adjunct for type 2 diabetes—not as a precisely dosed treatment or a substitute for established care.

Lipid results depend on what the tea replaced

The lipid findings deserve more caution than a headline such as "herbal tea lowers cholesterol." Total cholesterol, LDL cholesterol, and triglycerides fell significantly only in the trials that compared herbal tea with water or placebo: P=0.024, P=0.037, and P=0.043, respectively. The review described these effects as medium in size.

When the comparison beverage was active—such as another herbal infusion—the lipid advantages disappeared. This is a central result, not a footnote. It suggests that any benefit may depend partly on beverage substitution. Replacing a sweet drink with an unsweetened herbal tea could plausibly help a person's overall diet; replacing one polyphenol-containing drink with another may do little for lipids.

Those lipid outcomes are biomarkers, not evidence that herbal tea prevents heart attacks, strokes, kidney disease, or diabetes complications. No such patient outcomes appear in the pooled findings.

Why polyphenols make the result plausible

Herbal teas deliver polyphenols, a broad group of plant compounds that can interact with carbohydrate digestion, insulin signaling, oxidative stress, and gut microbes. Biological plausibility helps explain why a trial result may be worth investigating; it does not prove that a cup of tea works through any one pathway in people.

Anthocyanins provide the strongest related human evidence. A 2024 meta-analysis of randomized trials of anthocyanin supplementation in people with type 2 diabetes reported significant improvements in HbA1c, fasting glucose, and cardiovascular biomarkers. Anthocyanins are prominent in hibiscus and berry-based preparations, so this finding supports the broader idea that some colorful plant compounds can affect metabolic biomarkers.

The microbiome hypothesis is also credible but remains indirect for herbal tea. A 2025 meta-analysis of 54 randomized trials, including 3,390 participants with type 2 diabetes, found that microbiome-targeted therapies lowered fasting plasma glucose by 7.97 mg/dL versus control (95% CI, -10.82 to -5.12; P<0.00001). Herbal polyphenols can be transformed by colonic microbes into other compounds, but that does not establish that this pathway caused the tea results.

The same distinction applies to the appealing claim that plant-compound combinations outperform isolated compounds. Herbal infusions contain many compounds, and a 2025 randomized-trial meta-analysis of Mediterranean-style diets found improvements in glycemic control, body mass index, lipids, and blood pressure in adults with type 2 diabetes. Yet no head-to-head herbal-tea trial in this evidence base tested a mixed polyphenol preparation against a single compound. The combination claim remains a hypothesis.

Why the pooled result may not travel well

Fourteen trials and 551 participants work out to about 39 participants per trial on average. Small trials can produce unstable estimates, especially when researchers split results by control drink, duration, dose, region, or participant characteristics. In this review, trial duration, geographic region, and the proportion of male participants significantly moderated the fasting-glucose and HbA1c findings. Control type significantly moderated total-cholesterol and LDL-cholesterol results.

Those moderators mean the average result may conceal important differences among settings. Dietary background, customary preparation methods, participant mix, and the control beverage could all affect what a trial detects. The current data do not establish whether benefits extend to prediabetes, metabolic syndrome, or people without diabetes. They also do not show whether effects persist over long periods or add meaningfully to standard diabetes drugs.

Dose is another unresolved problem. The trials used 2 to 20 grams per day of plant material, a tenfold range, without an actionable dose-response curve. Brewing variables add more uncertainty: plant part, harvest conditions, storage, water temperature, and steeping time can all change what ends up in the cup. A consumer product labeled "hibiscus tea" is not necessarily comparable with an intervention used in a trial.

Publication bias also remains possible. The available evidence does not include a clear body of published null-result trials, and the limited study count makes a positive literature easier to overread. The absence of negative evidence is not proof that negative results do not exist.

How herbal tea compares with interventions that have clearer numbers

For type 2 diabetes, herbal tea belongs below the interventions with larger and more precise evidence bases. A 2022 dose-response meta-analysis of carbohydrate restriction included 50 randomized trials and 4,291 patients, and estimated effects for each 10% reduction in carbohydrate intake at six months. That scale and dose-response design allow more practical interpretation than the tea literature currently permits.

Other dietary changes also have direct randomized evidence. A systematic review of 80 randomized trials found that whole-grain intake, compared with refined grains, improved post-meal glycemia and insulin responses and modestly improved HbA1c, though it did not improve fasting glucose, fasting insulin, or HOMA-IR. The comparison matters: replacing refined grains with whole grains is a defined dietary change. "Drink more herbal tea" is still an umbrella instruction with too many unknowns underneath it.

What to do with this evidence

For someone with type 2 diabetes who enjoys unsweetened herbal tea, drinking it regularly is a reasonable low-risk habit, particularly if it replaces sugar-sweetened beverages. Anthocyanin-rich options such as hibiscus have the best mechanistic rationale among commonly discussed teas, but the current pooled evidence cannot name a winning species, a best brew, or a reliable daily dose.

Use herbal tea as food, not as a treatment plan. Continue prescribed medication and glucose monitoring, and discuss meaningful dietary changes with the clinician managing your diabetes—especially if you take glucose-lowering drugs or have kidney, liver, or blood-pressure concerns. The evidence says these beverages may nudge metabolic biomarkers in a favorable direction. It does not yet say how large that nudge is, who gets it, or whether it lasts.